1
|
9/F/1
|
PUCS/face, scalp, extremities
|
FHSL
|
Medium/dermis
|
EBV+ cells in interfollicular area of LN
|
324
|
CD8
|
Chemotherapy (IMR) and Radiotherapy. Maintained herbal remedy
|
CR
|
AWD
|
8.7Y
|
2
|
13/F/3
|
Erythema, PUCS/face, extremities, and areas not exposed to sun
|
FHSL
|
Medium/dermis and fatty tissue/Fatty tissue necrosis
|
EBV+ cells diffusely infiltrated LN
|
624
|
CD56
|
Chemotherapy (NHL-BFM-90) for 3 cycles [14]
|
PD
|
DOD
|
1.1Y
|
3
|
8/M/1
|
PUCS, nodules/face, extremities
|
FHSL
|
Medium/dermis
|
EBV+ cells present in interfollicular area of LN
|
450
|
CD56
|
Chemotherapy (MTX + VP-16) and Radiotherapy
|
PR
|
AWD
|
7.6Y
|
4
|
4/M/1
|
PUCS/ areas exposed to sun; HMB
|
Fever
|
Small and medium/dermis and subcutaneous tissue
|
ND
|
NA
|
CD4
|
Herbal remedy
|
PD
|
AWD
|
6Y
|
5
|
5/M/1
|
PUCS, nodules/face, extremities
|
FHS
|
Small and medium/dermis
|
ND
|
NA
|
CD8
|
Chemotherapy (IMR) and Radiotherapy. Maintained Herbal remedy
|
PD
|
DOD
|
4.4Y
|
6
|
8/F/1.5
|
PUCS/face, arms, areas not exposed to sun
|
FHSL
|
Medium and large/dermis
|
ND
|
NA
|
CD56
|
NA
|
NA
|
DOD
|
3Y
|
7
|
10/M/3
|
PUCS/face, extremities, HMB
|
FL
|
Small and medium/dermis and subcutaneous tissue
|
ND
|
298.4
|
CD8
|
Chemotherapy (NHL-BFM-95) for 6 cycles [15]
|
PR
|
DOD
|
2.2Y
|
8
|
2/F/0.5
|
PUCS, nodules/face, extremities
|
None
|
Medium/dermis and subcutaneous tissue
|
ND
|
NA
|
CD56
|
NA
|
NA
|
LFU
|
LFU
|
9
|
21/M/14
|
PUCS/areas exposed and unexposed to sun; HMB
|
FSHLNP nodules, HPS
|
Medium and large/dermis and subcutaneous tissue
|
EBV+ cells diffusely infiltrated LN and BM
|
1202
|
CD4
|
Chemotherapy (GEM+VP16 + MTX + P-ASP+thalidomide for 6 cycles)
|
PR
|
DOD
|
0.6Y
|
10
|
7/F/1
|
PUCS/face, extremities,
|
Fever
|
Medium/dermis and fatty tissue
|
ND
|
NA
|
CD8
|
NA
|
NA
|
LFU
|
LFU
|
11
|
5/M/2
|
PUCS, nodules/face, extremities, trunk; HMB
|
FHSL
|
Medium/dermis
|
EBV+ cells in interfollicular area of LN
|
318
|
CD4
|
Chemotherapy (NHL-BFM-95) for 6 cycles; Sibling HSCT; and EBV-CTL treatment [15]
|
CR
|
Alive without disease
|
4.4Y
|
12
|
13/F/1
|
PUCS/face, extremities, trunk, and oral cavity
|
FL
|
Medium/dermis
|
BM-
|
482
|
CD56
|
Chemotherapy (P-ASP+GEM+L-OHP) Maintained herbal remedy
|
PD
|
DOD
|
2.2Y
|
13
|
12/F/2
|
PUCS, nodules/face, trunk, and extremities
|
FHSL
|
Medium/dermis and fatty tissue
|
EBV+ cells diffusely infiltrated LN and BM
|
358.9
|
CD56
|
Chemotherapy (GEM for 6 cycles) and antivirus treatment (Ganciclovir)
|
CR
|
AWD
|
3.2Y
|
14
|
5/M/3
|
PUCS/face, extremities, trunk
|
FL
|
Medium/dermis and subcutaneous tissue
|
BM-
|
334.6
|
CD4
|
Chemotherapy (First Line: GEM for 6 cycles, Second Line: VP-16 + VCR for 1 cycle, Third Line: VLB + PDN for 1 cycle)
|
PR
|
AWD
|
2.9Y
|
15
|
7/F/4
|
PUCS/face, extremities
|
FL
|
Medium/dermis
|
BM-
|
323.2
|
CD56
|
Chemotherapy (GEM for 6 cycles)
|
CR
|
DOD
|
1.3Y
|
16
|
12/F/4
|
PUCS/face, trunk, arms and legs; HMB
|
FHSL
|
Medium/dermis and fatty tissue
|
BM-
|
NA
|
CD4
|
NA
|
NA
|
DOD
|
0.7Y
|
17
|
11/M/9
|
PUCS, nodules/face, arms, legs, and areas not exposed to sun; HMB
|
FHSL
|
Medium/dermis and subcutaneous tissue
|
EBV+ cells diffusely infiltrated LN and BM
|
585
|
CD4
|
Chemotherapy (First Line: NHL-BFM-95, Second Line: GEM for 2 cycles) [15]
|
PD
|
DOD
|
2.4Y
|
18
|
8/M/2
|
PUCS/face, arms, legs, and trunk
|
Fever
|
Medium/dermis and subcutaneous tissue
|
BM-
|
312
|
CD4
|
Chemotherapy (methylprednisolone, azithromycin, acitretin, and cyclosporine)
|
PR
|
AWD
|
2.2Y
|
19
|
F/5/3
|
PUCS/face, legs, and trunk
|
Fever
|
Medium/dermis and subcutaneous tissue
|
ND
|
NA
|
CD8
|
NA
|
NA
|
LFU
|
LFU
|